Bingnan Zhang

5PUBLICATIONS
54CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 23, 2026
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity.

|Oct 30, 2025
Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer.

Alissa J Cooper, Benjamin Herzberg, Mitchell Parma

|Oct 24, 2025
Sacituzumab govitecan: another emerging treatment option for patients with relapsed small cell lung cancer.

Bingnan Zhang, Carl M Gay

|Aug 16, 2024
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities.

C Allison Stewart, Lixia Diao, Yuanxin Xi

|Mar 09, 2019
Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.

Bingnan Zhang, Elisa F Long

Pageof 1

Frequent Collaborators

3 joint publications

Lauren Averett Byers

2 joint publications

John Victor Heymach

2 joint publications

Janet Tu

2 joint publications

Mitchell Parma